Please ensure Javascript is enabled for purposes of website accessibility

How Zoetis Beat Expectations Again in Q2

By Keith Speights – Aug 6, 2020 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its companion-animal products continue to be the sweet spot for the animal health company.

Zoetis (ZTS -1.76%) lowered expectations for 2020 in May because of the coronavirus pandemic. But the animal health company's shares didn't perform below expectations. Its stock is up more than 20% over the last three months.

That momentum seems likely to continue. Zoetis announced its second-quarter results before the market opened on Thursday. Here are the highlights from the company's Q2 update.

Smiling female veterinarian with dog licking her face.

Image source: Getty Images.

By the numbers

Zoetis reported revenue in the second quarter of $1.5 billion, flat compared with its revenue in the prior-year period. But this result still topped the consensus Wall Street Q2 revenue estimate of $1.36 billion.

The company announced net income in Q2 of $377 million, or $0.79 per share, based on generally accepted accounting principles (GAAP). This reflected modest improvement from GAAP earnings of $371 million, or $0.77 per share, posted in the same quarter of 2019. Zoetis recorded adjusted earnings of $427 million, or $0.89 per share. While this was down slightly from adjusted earnings of $436 million, or $0.90 per share, in the prior-year period, it handily beat the average analysts' earnings estimate of $0.64 per share.

Behind the numbers

The U.S. market served as a bright spot for Zoetis in the second quarter. U.S. revenue rose 6% year over year to $832 million. The company reported that sales for its companion-animal products jumped 19% thanks largely to higher demand for its Simparica brands. The company's recent acquisitions of Platinum Performance and several regional diagnostic reference labs also contributed to the U.S. revenue growth. But U.S. livestock-products revenue sank 18% year over year. 

International sales fell 5% year over year to $708 million. Foreign exchange fluctuations made a big difference, though. On a constant-currency basis, the company's international revenue increased by 3%. Several brands performed pretty well in Q2, including Apoquel and Cytopoint dermatology products. Zoetis' companion-animal products business in China also grew rapidly in the second quarter.

The coronavirus pandemic did hurt Zoetis in Q2, however. The shift from U.S. consumers dining out to eating at home affected producer profitability and disrupted the food supply chain to some extent. Visits to veterinary clinics fell in some European and Latin American markets, weighing on growth for companion-animal product sales.

Looking ahead

Zoetis now anticipates revenue of $6.3 billion to $6.475 billion in full-year 2020, up from its previous guidance of $5.95 billion to $6.25 billion. The company also projects 2020 earnings per share of $3.14 to $3.32, compared to $2.80 to $3.07 provided in its previous outlook. Adjusted EPS is expected to be between $3.52 and $3.68, up from the previous guidance of $3.17 to $3.42.

CEO Kristin Peck said that the company's higher full-year guidance reflects an improved outlook. She stated that Zoetis expects "overall revenue growth for the remainder of the year to be driven largely by companion animal products, especially parasiticides and our key dermatology portfolio." How the pandemic will impact markets remains the biggest question mark for the healthcare stock, though.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of Zoetis. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zoetis Inc. Stock Quote
Zoetis Inc.
ZTS
$148.29 (-1.76%) $-2.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.